Invesco Ltd. lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,498,093 shares of the medical research company's stock after selling 92,167 shares during the period. Invesco Ltd. owned about 1.44% of IQVIA worth $440,414,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Canada Pension Plan Investment Board increased its stake in IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after buying an additional 798,534 shares in the last quarter. Northern Trust Corp boosted its position in shares of IQVIA by 16.2% during the 4th quarter. Northern Trust Corp now owns 1,791,229 shares of the medical research company's stock valued at $351,994,000 after purchasing an additional 250,141 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in IQVIA by 13.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock worth $273,766,000 after buying an additional 167,057 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in IQVIA by 18.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,387,862 shares of the medical research company's stock worth $272,744,000 after buying an additional 214,046 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA Trading Down 0.4%
Shares of NYSE:IQV traded down $0.73 during mid-day trading on Thursday, reaching $189.50. 946,070 shares of the company's stock were exchanged, compared to its average volume of 1,995,609. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market capitalization of $32.21 billion, a price-to-earnings ratio of 27.42, a PEG ratio of 2.04 and a beta of 1.30. The business's fifty day moving average price is $168.77 and its 200-day moving average price is $169.04.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.64 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the company. Truist Financial raised their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Barclays raised their price objective on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Robert W. Baird upped their target price on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $228.62.
Check Out Our Latest Stock Analysis on IQV
Insider Activity
In other news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Stories

Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.